DelveInsight's "Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Retinal Vein Occlusion market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Retinal Vein Occlusion market shares of the individual therapies, a detailed current Retinal Vein Occlusion treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Retinal Vein Occlusion is an interruption of the normal venous drainage from the retinal tissue. Either the central vein or one of its branches can become occluded. Uncommonly, the occlusion can occur in a vein that drains half of the retina. This is referred to as a hemiretinal vein occlusion (HRVO).
There’s no medication available that’s specific for retinal artery occlusions. Most people with this condition will have permanent changes to their vision.
Retinal Vein Occlusion Market Key Facts
- As per the study by Laouri et al. titled, “The burden of disease of retinal vein occlusion: review of the literature,” the age and sex standardized prevalence was found to be 5.20 (per 1000) for any RVO, 4.42 for BRVO, and 0.80 for CRVO in the population aged ≥30 years.
- The study titled “Prevalence of Retinal Vein Occlusion in Europe: A Systematic Review and Meta-Analysis” conducted by Li et al., found the prevalence of RVO in Europe to be 0.7% in persons aged 55 years and older based on the examination of individuals from four prevalence studies.
- According to the study conducted by Kolar et al., titled “Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data,” RVO is more prevalent in men than women and is more frequent in older age (over 65 years).
- According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Retinal Vein Occlusion.
Retinal Vein Occlusion Market Size
The anti-VEGF drugs segment dominated the market due to preference for these drugs as the first line of treatment for BRVO. The rise in the prevalence of risk factors such as diabetes and glaucoma will be one of the key factors for the rise in the Retinal Vein Occlusion patient pool.
The Retinal Vein Occlusion market analysis section of the report helps to understand the current and forecasted Retinal Vein Occlusion market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Retinal Vein Occlusion Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The available therapeutics treatment options in RVO Landscape aim to reduce complications such as macular edema and neovascularization. The rise in prevalence of eye diseases globally, increase in geriatric population, improved health care infrastructure, and upcoming novel treatments are expected to drive the Retinal Vein Occlusion Market Growth.
Companies in the Retinal Vein Occlusion Market include Graybug Vision, Kodiak Sciences, Panoptes Pharma, Outlook Therapeutics, and many more. Retinal Vein Occlusion Therapies covered in the report include PaniJect, ONS-5010, GB-102, KSI-301, and many more.
Retinal Vein Occlusion Epidemiology Segmentation
- Total Prevalent Cases of Retinal Vein Occlusion
- Type-Specific Prevalent Cases of Retinal Vein Occlusion
- Gender-Specific Prevalent Cases of Retinal Vein Occlusion
- Age-Specific Prevalent Cases of Retinal Vein Occlusion
- Diagnosed and Treatable Cases of Retinal Vein Occlusion
Retinal Vein Occlusion Epidemiology Forecast
The Retinal Vein Occlusion epidemiology section covers insights about historical and current Retinal Vein Occlusion patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Retinal Vein Occlusion Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Retinal Vein Occlusion Market Size